Senseonics (NYSE:SENS) Rating Increased to Strong-Buy at Mizuho

Senseonics (NYSE:SENS - Get Free Report) was upgraded by Mizuho to a "strong-buy" rating in a report released on Wednesday, April 9th,Zacks.com reports.

Several other research analysts also recently commented on the company. StockNews.com began coverage on Senseonics in a report on Thursday, December 26th. They issued a "sell" rating on the stock. HC Wainwright restated a "buy" rating and issued a $2.00 target price on shares of Senseonics in a report on Wednesday, March 5th.

Senseonics Stock Performance

NYSE SENS traded down $0.01 during trading on Wednesday, hitting $0.60. 1,126,046 shares of the company's stock traded hands, compared to its average volume of 6,256,942. The stock has a market capitalization of $388.24 million, a price-to-earnings ratio of -4.58 and a beta of 0.84. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The business has a 50 day moving average of $0.77 and a 200-day moving average of $0.59. Senseonics has a 12-month low of $0.25 and a 12-month high of $1.40.

Senseonics (NYSE:SENS - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same period in the previous year, the firm earned ($0.07) earnings per share. As a group, equities research analysts anticipate that Senseonics will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new position in shares of Senseonics during the fourth quarter valued at about $26,000. HighTower Advisors LLC purchased a new position in shares of Senseonics in the 4th quarter valued at approximately $32,000. Two Sigma Investments LP bought a new stake in shares of Senseonics during the fourth quarter valued at approximately $36,000. FMR LLC grew its stake in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company's stock worth $59,000 after purchasing an additional 167,970 shares during the period. Finally, Ridgecrest Wealth Partners LLC bought a new position in Senseonics in the fourth quarter worth $60,000. Institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.